ERBB2 and triple-negative breast carcinoma: ST8176AA1 could be an alternative or a companion drug to T-DM1 for the treatment of ErbB2+ tumors and a unique therapeutic opportunity for triple negative breast cancer that might be inhibited by ST8176AA1 and also be made sensitive to tamoxifen standard therapies.